{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:50:35Z","timestamp":1777517435950,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Serum prostate-specific antigen (PSA) concentrations after radical prostatectomy typically become undetectable with the use of current immunometric assay methods. Despite modern surgical techniques, 15%\u201330% of prostate cancer patients undergoing radical prostatectomy develop a biochemical recurrence during follow-up. Unfortunately, poor analytical sensitivity of standard PSA assays delays biochemical recurrence detection, and because of day-to-day assay imprecision ultrasensitive PSA assays cannot assess PSA kinetics. We developed an immuno-PCR assay for total PSA that has a limit of quantification &amp;gt;10 times lower than current ultrasensitive assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>The 2-site immunometric assay for total PSA employed 2 monoclonal antibodies, one conjugated to a double-stranded DNA label and the other bound to paramagnetic microparticles. After several washing steps, quantification cycles were determined and values were converted to PSA concentrations. We characterized analytical performance and compared accuracy with a commercially available total PSA assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The limit of quantification was 0.65 ng\/L and the assay was linear in the range of 0.25\u2013152.0 ng\/L. Total imprecision estimates at PSA concentrations of 3.8, 24.1, and 69.1 ng\/L were &amp;lt;15.2%, &amp;lt;9.4%, and &amp;lt;10.6%, respectively. Recovery of supplemented PSA ranged from 87.5% to 119.2% (mean 100.3%). Dilution recovery ranged from 96.4% to 115.3% (mean 102.3%). There was no high-dose hook effect up to 50 000 ng\/L of PSA. Comparison with the commercial PSA assay showed a regression slope of 1.06 and a correlation coefficient of 0.996.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The analytical characteristics of the assay support the use of this assay for the accurate and precise measurement of serum PSA, even at sub\u2013nanogram-per-liter concentrations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2011.170290","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T04:47:39Z","timestamp":1330058859000},"page":"732-740","source":"Crossref","is-referenced-by-count":27,"title":["Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology"],"prefix":"10.1093","volume":"58","author":[{"given":"Jonathan E","family":"McDermed","sequence":"first","affiliation":[{"name":"Iris Molecular Diagnostics, a Division of IRIS International, Inc., Carlsbad, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Sanders","sequence":"first","affiliation":[{"name":"Iris Molecular Diagnostics, a Division of IRIS International, Inc., Carlsbad, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Fait","sequence":"first","affiliation":[{"name":"Iris Molecular Diagnostics, a Division of IRIS International, Inc., Carlsbad, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E","family":"Klem","sequence":"first","affiliation":[{"name":"Iris Molecular Diagnostics, a Division of IRIS International, Inc., Carlsbad, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J","family":"Sarno","sequence":"first","affiliation":[{"name":"Iris Molecular Diagnostics, a Division of IRIS International, Inc., Carlsbad, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H","family":"Adams","sequence":"first","affiliation":[{"name":"Iris Molecular Diagnostics, a Division of IRIS International, Inc., Carlsbad, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios P","family":"Diamandis","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Department of Clinical Biochemistry, University Health Network"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,4,1]]},"reference":[{"key":"2020022705042499600_B1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/10408369891234219","article-title":"Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate","volume":"35","author":"Rittenhouse","year":"1998","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2020022705042499600_B2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"2020022705042499600_B3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N Engl J Med"},{"key":"2020022705042499600_B4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMp1111894","article-title":"One man at a time: resolving the PSA controversy","volume":"365","author":"McNaughton-Collins","year":"2011","journal-title":"N Engl J Med"},{"key":"2020022705042499600_B5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-5347(17)38491-4","article-title":"Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate [Review]","volume":"145","author":"Oesterling","year":"1991","journal-title":"J Urol"},{"key":"2020022705042499600_B6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/clinchem\/39.2.181","article-title":"Prostate specific antigen: biochemistry, analytical methods and clinical application [Review]","volume":"38","author":"Armbruster","year":"1993","journal-title":"Clin Chem"},{"key":"2020022705042499600_B7","first-page":"802","article-title":"Clinical use of prostate specific antigen in patients with prostate cancer","volume":"145","author":"Hudson","year":"1991","journal-title":"J Urol"},{"key":"2020022705042499600_B8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N Engl J Med"},{"key":"2020022705042499600_B9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0022-5347(17)41175-X","article-title":"Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate","volume":"141","author":"Stamey","year":"1989","journal-title":"II. Radical prostatectomy treated patients. J Urol"},{"key":"2020022705042499600_B10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-5347(01)65082-1","article-title":"Detection of prostate cancer relapse with prostate specific antigen monitoring levels of 0.001 to 0.1ug\/L","volume":"157","author":"Yu","year":"1997","journal-title":"J Urol"},{"key":"2020022705042499600_B11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0009-9120(99)00099-5","article-title":"Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up","volume":"33","author":"Vassilikos","year":"2000","journal-title":"Clin Biochem"},{"key":"2020022705042499600_B12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/clinchem\/42.6.853","article-title":"Ultrasensitive prostate specific antigen assays and their clinical application","volume":"42","author":"Diamandis","year":"1996","journal-title":"Clin Chem"},{"key":"2020022705042499600_B13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/clinchem\/42.5.675","article-title":"Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers","volume":"42","author":"Ferguson","year":"1996","journal-title":"Clin Chem"},{"key":"2020022705042499600_B14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0090-4295(97)00251-3","article-title":"Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay","volume":"50","author":"Ellis","year":"1997","journal-title":"Urology"},{"key":"2020022705042499600_B15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0022-5347(01)64962-0","article-title":"Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy","volume":"157","author":"Witherspoon","year":"1997","journal-title":"J Urol"},{"key":"2020022705042499600_B16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0090-4295(94)80013-8","article-title":"Development of a highly sensitive immunochemiluminometric assay for prostate-specific antigen","volume":"44","author":"Klee","year":"1994","journal-title":"Urology"},{"key":"2020022705042499600_B17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1442-2042.1998.tb00411.x","article-title":"Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy","volume":"5","author":"Arai","year":"1998","journal-title":"Int J Urol"},{"key":"2020022705042499600_B18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0022-5347(01)61635-5","article-title":"Ultrasensitive detection of prostate specific antigen in the follow-up of 422 patients after radical prostatectomy","volume":"16","author":"Haese","year":"1999","journal-title":"J Urol"},{"key":"2020022705042499600_B19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.urology.2010.03.081","article-title":"Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy","volume":"76","author":"Hong","year":"2010","journal-title":"Urology"},{"key":"2020022705042499600_B20","doi-asserted-by":"crossref","first-page":"18437","DOI":"10.1073\/pnas.0904719106","article-title":"Nanoparticle-based bio-barcode assay redefines \u201cundetectable\u201d PSA and biochemical recurrence after radical prostatectomy","volume":"106","author":"Thaxton","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020022705042499600_B21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2020022705042499600_B22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.1439758","article-title":"Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates","volume":"258","author":"Sano","year":"1992","journal-title":"Science"},{"key":"2020022705042499600_B23","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1093\/nar\/21.25.6038","article-title":"Universal Immuno-PCR for ultra-sensitive target protein detection","volume":"21","author":"Zhou","year":"1993","journal-title":"Nucleic Acids Res"},{"key":"2020022705042499600_B24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/clinchem\/41.9.1371","article-title":"Analyte detection with DNA-labeled antibodies and polymerase chain reaction","volume":"41","author":"Joerger","year":"1995","journal-title":"Clin Chem"},{"key":"2020022705042499600_B25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/nar\/23.3.522","article-title":"High sensitivity multianalyte immunoassay using covalent DNA-labeled antibodies and polymerase chain reaction","volume":"23","author":"Hendrickson","year":"1995","journal-title":"Nucleic Acids Res"},{"issue":"S10","key":"2020022705042499600_B26","first-page":"A-18","article-title":"Development and analytical validation of a new prostate-specific antigen (PSA) assay (NADiA\u00ae ProsVue\u2122), based on immuno-PCR technology","volume":"57","author":"McDermed","year":"2011","journal-title":"Clin Chem"},{"key":"2020022705042499600_B27","unstructured":"McDermed\n              JE\n            , KlemRE, AdamsTH, DiamandisEP, FreedlandSJ. Postprostatectomy PSA determined with a nucleic acid detection immuno-PCR assay (NADiA) as a prognostic indicator for risk of prostate cancer recurrence [Abstract]. In: ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer; 2010 Oct 18\u201320; Hollywood, FL. Abstract no. 105. http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=101&abstractID=60963 (Accessed March 2012)."},{"key":"2020022705042499600_B28","doi-asserted-by":"crossref","unstructured":"Moul\n              JW\n            , SemmesOJ, VessellaRL, McDermedJE, LiljaH. Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA [Abstract]. J Clin Oncol2011;29(Suppl 7):47. http:\/\/www.asco.org\/ASCOv2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=104&abstractID=72511 (Accessed March 2012).","DOI":"10.1200\/jco.2011.29.7_suppl.47"},{"key":"2020022705042499600_B29","doi-asserted-by":"crossref","unstructured":"Moul\n              J\n            , SemmesJ, VessellaR, SarnoM, TriebellM, LiljaH. NADiA ProsVue\u2122 slope identifies patients at greatly reduced risk for prostate cancer recurrence following radical prostatectomy. In: Proceedings of the AUA Annual Meeting; 2011 May 14\u201319; Washington, DC. Abstract no. 1915. http:\/\/www.aua2011.org\/abstracts\/search.cfm (Accessed March 2012).","DOI":"10.1016\/j.juro.2011.02.2053"},{"key":"2020022705042499600_B30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj0940023C","article-title":"A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin","volume":"94","author":"Green","year":"1965","journal-title":"Biochem J"},{"key":"2020022705042499600_B31","volume-title":"Protocols for determination of limits of detection and limits of quantification; approved guideline. CLSI document EP17-A.","author":"CLSI.","year":"2004"},{"key":"2020022705042499600_B32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","article-title":"An analysis of variance test for normality (complete samples)","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"key":"2020022705042499600_B33","volume-title":"Evaluation of linearity of quantitative measurement procedures: a statistical approach; approved guideline. CLSI document EP6-A.","author":"CLSI.","year":"2003"},{"key":"2020022705042499600_B34","volume-title":"Evaluation of precision performance of quantitative measurement methods; approved guideline.","author":"CLSI.","year":"2004","edition":"2nd ed."},{"key":"2020022705042499600_B35","unstructured":"Siemens.\n          ADVIA Centaur PSA assay specifications.\nhttp:\/\/www.medical.siemens.com\/siemens\/en_GLOBAL\/gg_diag_FBAs\/files\/Assays\/hisstory\/0700068.pdf (Accessed March 2012)."},{"key":"2020022705042499600_B36","volume-title":"Method comparison and bias estimation using patient samples.","author":"CLSI.","year":"2002","edition":"2nd ed."},{"key":"2020022705042499600_B37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000109723","article-title":"Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy","volume":"79","author":"Shimizu","year":"2007","journal-title":"Urol Int"},{"key":"2020022705042499600_B38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2006.06294.x","article-title":"The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy","volume":"98","author":"Taylor","year":"2006","journal-title":"BJU Int"},{"key":"2020022705042499600_B39","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1464-410X.2009.08680.x","article-title":"Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group","volume":"104","author":"Teeter","year":"2009","journal-title":"BJU Int"},{"key":"2020022705042499600_B40","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.juro.2011.07.119","article-title":"Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment","volume":"196","author":"Reese","year":"2011","journal-title":"J Urol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/4\/732\/32657078\/clinchem0732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/4\/732\/32657078\/clinchem0732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T10:07:00Z","timestamp":1582798020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/58\/4\/732\/5620552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,1]]},"published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2011.170290","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,4,1]]},"published":{"date-parts":[[2012,4,1]]}}}